TY - JOUR
T1 - Trimethylamine N-Oxide Binds and Activates PERK to Promote Metabolic Dysfunction
AU - Chen, Sifan
AU - Henderson, Ayana
AU - Petriello, Michael C.
AU - Romano, Kymberleigh A.
AU - Gearing, Mary
AU - Miao, Ji
AU - Schell, Mareike
AU - Sandoval-Espinola, Walter J.
AU - Tao, Jiahui
AU - Sha, Bingdong
AU - Graham, Mark
AU - Crooke, Rosanne
AU - Kleinridders, Andre
AU - Balskus, Emily P.
AU - Rey, Federico E.
AU - Morris, Andrew J.
AU - Biddinger, Sudha B.
N1 - Publisher Copyright:
© 2019
PY - 2019/12/3
Y1 - 2019/12/3
N2 - The gut-microbe-derived metabolite trimethylamine N-oxide (TMAO) is increased by insulin resistance and associated with several sequelae of metabolic syndrome in humans, including cardiovascular, renal, and neurodegenerative disease. The mechanism by which TMAO promotes disease is unclear. We now reveal the endoplasmic reticulum stress kinase PERK (EIF2AK3) as a receptor for TMAO: TMAO binds to PERK at physiologically relevant concentrations; selectively activates the PERK branch of the unfolded protein response; and induces the transcription factor FoxO1, a key driver of metabolic disease, in a PERK-dependent manner. Furthermore, interventions to reduce TMAO, either by manipulation of the gut microbiota or by inhibition of the TMAO synthesizing enzyme, flavin-containing monooxygenase 3, can reduce PERK activation and FoxO1 levels in the liver. Taken together, these data suggest TMAO and PERK may be central to the pathogenesis of the metabolic syndrome.
AB - The gut-microbe-derived metabolite trimethylamine N-oxide (TMAO) is increased by insulin resistance and associated with several sequelae of metabolic syndrome in humans, including cardiovascular, renal, and neurodegenerative disease. The mechanism by which TMAO promotes disease is unclear. We now reveal the endoplasmic reticulum stress kinase PERK (EIF2AK3) as a receptor for TMAO: TMAO binds to PERK at physiologically relevant concentrations; selectively activates the PERK branch of the unfolded protein response; and induces the transcription factor FoxO1, a key driver of metabolic disease, in a PERK-dependent manner. Furthermore, interventions to reduce TMAO, either by manipulation of the gut microbiota or by inhibition of the TMAO synthesizing enzyme, flavin-containing monooxygenase 3, can reduce PERK activation and FoxO1 levels in the liver. Taken together, these data suggest TMAO and PERK may be central to the pathogenesis of the metabolic syndrome.
KW - EIF2AK3
KW - FoxO1
KW - PERK
KW - diabetes
KW - endoplasmic reticulum stress
KW - insulin signaling
KW - metabolomics
KW - trimethylamine N-oxide
UR - http://www.scopus.com/inward/record.url?scp=85075446550&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075446550&partnerID=8YFLogxK
U2 - 10.1016/j.cmet.2019.08.021
DO - 10.1016/j.cmet.2019.08.021
M3 - Article
C2 - 31543404
AN - SCOPUS:85075446550
SN - 1550-4131
VL - 30
SP - 1141-1151.e5
JO - Cell Metabolism
JF - Cell Metabolism
IS - 6
ER -